A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization

Cancer

Volumn 88, Issue 1, 2000, Pages 50-57

  Lladó, Laura ^a   Virgili, Joan ^a   Figueras, Joan ^a   Valls, Carles ^a   Dominguez, Joan ^a   Rafecas, Antoni ^a   Torras, Jaume ^a   Fabregat, Joan ^a   Guardiola, Jordi ^b   Jaurrieta, Eduardo ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Department of Gastroenterology   (Spain)

Author keywords

Hepatocellular carcinoma; Palliative treatment; Prognosis; Transcatheter arterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; HUMAN; LIPID TRANSPORT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS;

EID: 0033972909     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<50::AID-CNCR8>3.0.CO;2-I     Document Type: Article

References (32)

1. Okuda K, Ohtsuki T, Obata H, Obata H, Tomimatsu M, Okazaki N, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment, Study of 850 patients. Cancer 1985;4:918-27.
2. Okuda K, Liver Cancer Study Group of Japan. Primary liver cancers in Japan. Cancer 1980;45:2663-9.
3. Bismuth H, Houssin D, Ornowski J, Meriggi F. Liver resection in cirrhotic patients: a Western experience. World J Surg 1986;10:311-7.
4. Bruix J, Cirera I, Calvet X, Fuster J, Bru C, Ayuso C, et al. Surgical resection and survival in Western patients with hepatocellular carcinoma. J Hepatol 1992;15:350-5.
5. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States, prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22.
6. Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma. Am J Surg 1997;173:358-65.
7. Lehnert T, Herfarth C. Chemoembolization for hepatocellular carcinoma. What, when, and for whom?. Ann Surg 1996; 224:1-3.
8. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 1993;72:3598-608.
9. Nagasue N, Kohno H, Uchida M. Evaluation of preoperative transcatheter arterial embolization in the treatment of resectable primary liver cancer. Semin Surg Oncol 1993;9:327-31.
10. Takenaka K, Yoshida K, Nishizaki T, Korenaga D, Hiroshige K, Ikeda T, et al. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg 1995;169:400-5.
11. Jaeger HJ, Mehring UM, Castaneda F, Hasse F, Blumhardt G, Loehlein D, et al. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radial 1996;19:388-96.
12. Bayraktar Y, Balkanci F, Kayhan B, Uzunalimoglu B, Gozok A, Ozisik A, et al. A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma. Hepato-Gastroenterology 1996;43:681-7.
13. Pelletier G, Roche A, Ink O, Anciaux M, Derby S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.
14. Pelletier G, Ducreux M, Broseta V, Hagége H, Dao T, Van Steenbergen V, et al. Groupe CHC 2. Essai randomisé de la chimioembolisation lipiodolèe (CEL) dans le traitment du carcinome hèpatocellulaire (CHC) non rèsècable [abstract]. Gastroenterol Clin Biol 1996;20:A182.1.
15. Groupe D'etude et de traitement du carcinome hèpatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
16. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985;154:15-7.
17. Valls C, Pamies JJ, Sancho C, Benasco C, Figueras J, Dominguez J, et al. Computed tomography after lipiodol chemoembolization in hepatocellular carcinoma. Eur Radiol 1994;4:238-42.
18. Valls C, Figueras J, Jaurrieta E, Sancho C, Dominguez J, Benasco C, et al. Hepatocellular carcinoma: iodized-oil CT TNM classification. AJR 1996;167:477-81.
19. Ngan H, Lai CL, Fan ST, Lai EC, Yuen WK, Tso WK. Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. J Vasc Int Radiol 1991;7(3):419-25.
20. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170:783-6.
21. Marcos-Alvarez A, Jenkins RL, Washburn WK, Lewis WD, Stuart KE, Gordon FD, et al. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg 1996;131(3):292-8.
22. Farinati F, De Maria N, Marafin C, Herszenyi L, Del Prato S, Rinaldi M, et al. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 1991;41:2332-9.
23. Okada S. Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology 1998;27:1743-4.
24. Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with HCC receiving systemic chemotherapy. Hepatology 1992;16:112-7.
25. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991;67:385-91.
26. Shijo H, Okazaki M, Higashihara H, Koganemaru F, Okumura M. Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization. Am J Gastroenterol 1992;87:1154-9.
27. Takeyasu K, Suzuki M, Uesaka K, Muramatsu Y, Moriyama N, Yoshida T. et al. Hepatic artery embolization for inoperable hepatocellular carcinoma: prognosis and risk factors. Cancer Chemother Pharmacol 1989;23(Suppl):S123-5.
28. Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991; 68:2150-4.
29. Akashi Y, Koreeda C, Enomoto S, Uchiyama S, Mizuno T, Shiozaki Y, et al. Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology 1991;14:262-8.
30. Mondazzi L, Bottelli R, Rrambilla G, Rampoldi A, Rezak-ovic I, Zavaglia C, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognosis factors. Hepatology 1994;19:1115-23.
31. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997;79:2087-94.
32. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni ME, Williams R. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.